Article
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 May 2015
Monk B J, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita A S, Nieto A, Park Y C, Cheng P S, Li W, Favis R, Ricci D, Poveda A
Abstract excerpt
BACKGROUND: We investigated the association of BRCA1 and XPG mutations with response rate (RR), progression-free survival (PFS) and overall survival (OS) in a subset of patients from a phase 3 clinical trial comparing the efficacy and safety of trabectedin + pegylated liposomal doxorubicin (PLD) versus PLD alone in patients with recurrent ovarian cancer. PATIENTS AND METHODS: A candidate array was designed based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.